[1]程 林.替格瑞洛对冠心病患者PCI治疗术后冠脉微循环功能的影响[J].医学信息,2020,33(07):156-157.[doi:10.3969/j.issn.1006-1959.2020.07.051]
　CHENG Lin.Effect of Ticagrelor on Coronary Microcirculation Function in Patients with Coronary Heart Disease After PCI Treatment[J].Medical Information,2020,33(07):156-157.[doi:10.3969/j.issn.1006-1959.2020.07.051]
点击复制

替格瑞洛对冠心病患者PCI治疗术后冠脉微循环功能的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年07期
页码:
156-157
栏目:
药物与临床
出版日期:
2020-04-01

文章信息/Info

Title:
Effect of Ticagrelor on Coronary Microcirculation Function in Patients with Coronary Heart Disease After PCI Treatment
文章编号:
1006-1959（2020）07-0156-02
作者:
程 林
（佳木斯市中心医院心内一科，黑龙江 佳木斯 154702）
Author(s):
CHENG Lin
(Department of Cardiology,Subject One,Jiamusi Central Hospital,Jiamusi 154702,Heilongjiang,China)
关键词:
替格瑞洛; 冠心病; 经皮冠状介入术; 微循环功能
Keywords:
Ticagrelor; Coronary heart disease; Percutaneous coronary intervention; Microcirculation function
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2020.07.051
文献标志码:
A
摘要:
目的 分析替格瑞洛应用于冠心病患者经皮冠状动脉介入（PCI）治疗术后，对冠脉微循环功能的影响。方法 选取2018年1月~2019年1月在我院进行PCI术治疗的50例冠心病患者为研究对象，采用随机数字表法分为对照组和观察组，各25例。对照组采用氯吡格雷，观察组采用替格瑞洛，比较治疗后两组凝血酶原时间（PT）、血小板聚集率（PAgT）和纤维蛋白原（Fbg）含量、循环抵抗指数（IMR）、超氧化物歧化酶（SOD）、丙二醛（MDA）、冠脉血流储备（CFR）、临床不良反应（呼吸困难、轻度出血）发生率及心血管事件发生情况。结果 治疗后观察组PT、PAgT、Fbg、IMR、MDA低于对照组，CFR、SOD高于对照组（P＜0.05）；治疗后观察组不良反应发生率为8.00%，与对照组的4.00%比较，差异无统计学意义（P＞0.05）；治疗后6个月观察组心血管事件发生率为4.00%，低于对照组的20.00%（P＜0.05）。结论 冠心病患者PCI术后应用替格瑞洛治疗，有助于改善冠脉微循环功能和凝血功能，临床不良反应少，且可降低远期心血管不良事件发生率，值得临床应用。
Abstract:
Objective To analyze the effect of ticagrelor on coronary microcirculation function after percutaneous coronary intervention (PCI) treatment in patients with coronary heart disease. Methods 50 patients with coronary heart disease who underwent percutaneous coronary intervention in our hospital from January 2018 to January 2019 were selected as the research object. They were divided into a control group and an observation group with a random number table method, 25 cases each. Clopidogrel was used in the control group and ticagrelor was used in the observation group. After treatment, the two groups of thrombin time (PT), platelet aggregation rate (PAgT), fibrinogen (Fbg) content, circulating resistance index (IMR) the incidence of superoxide dismutase (SOD), malondialdehyde (MDA), coronary flow reserve (CFR), clinical adverse reactions (dyspnea, mild bleeding) and the occurrence of cardiovascular events.Results The PT, PAgT, Fbg, IMR and MDA of the observation group after treatment were lower than the control group, and the CFR and SOD were higher than the control group(P<0.05); the incidence of adverse reactions in the observation group after surgery was 8.00%, and compared with 4.00% of the control group, the difference was not statistically significant(P> 0.05); the incidence of cardiovascular events in the observation group at 6 months after surgery was 4.00%, which was lower than 20.00% of the control grou(P<0.05).Conclusion The use of ticagrelor in patients with coronary heart disease after PCI is helpful to improve coronary microcirculation function and coagulation function, has fewer clinical adverse reactions, and can reduce the incidence of long-term cardiovascular adverse events. It is worthy of clinical application.

参考文献/References:

[1]吴龙梅,李幸洲,田新利,等.替格瑞洛在冠心病治疗中的研究进展[J].中国循证心血管医学杂志,2015,7(1):142-144. [2]李海滨,姜志安,刘向东,等.89例老年冠心病患者PCI术后支架内再狭窄的影响因素[J].中国老年学杂志,2015,35(18):5156-5157. [3]马文韬,颜红兵.新型的口服抗血小板药物替格瑞洛[J].中华老年心脑血管病杂志,2012,14(11):1217-1218. [4]卢周舟,童嘉毅.冠状动脉微循环障碍的检测与治疗[J].东南大学学报(医学版),2015,34(4):657-660. [5]王正东,李平,林智海.等.稳定性心绞痛老年患者经皮冠脉介入治疗后发生微循环障碍的相关因素分析[J].实用医学杂志,2015,31(20):3314-3317.

相似文献/References:

[1]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Medical Information,2018,31(07):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[2]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Medical Information,2018,31(07):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[3]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Medical Information,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[4]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Medical Information,2018,31(07):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Medical Information,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Medical Information,2018,31(07):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
　MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Medical Information,2018,31(07):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Medical Information,2018,31(07):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(07):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
　TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Medical Information,2022,35(07):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
[11]程 林.低剂量替格瑞洛治疗稳定型冠心病患者的疗效及安全性评价[J].医学信息,2020,33(08):161.[doi:10.3969/j.issn.1006-1959.2020.08.053]
　CHENG Lin.Efficacy and Safety of Low-dose Ticagrelor in the Treatment of Stable Coronary Heart Disease[J].Medical Information,2020,33(07):161.[doi:10.3969/j.issn.1006-1959.2020.08.053]

更新日期/Last Update: 2020-04-01